First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

NCT04396340 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped discontinued development program

Conditions

Ovarian Cancer
Nonsmall Cell Lung Cancer

Interventions

BIOLOGICAL: XMT-1592

Sponsor

Mersana Therapeutics

Collaborators

[object Object]